The drugmakers spent $1 billion to fund the development of biologic treatments for diseases such as Alzheimer’s and Parkinson’s disease, a new report shows.The drugmaker and its subsidiaries, Biogen Idec and Novartis, have committed to providing $2 billion in support for biologic development through their research and development arm, Biopharm, the report said.Biopharma also has…
개발 지원 대상
